To review direct comparative studies of the gonadotrophinreleasing hormone (GnRH) agonists goserelin, triptorelin, and leuprorelin for the treatment of prostate cancer, and identify whether there are meaningful clinical differences between these agents. In June 2017, the following searches were performed independently by two reviewers in PubMed: (i) 'prostate cancer' and 'triptorelin' and 'leuprorelin', (ii) 'prostate cancer' and 'triptorelin' and 'goserelin', and (iii) 'prostate cancer' and 'goserelin' and 'leuprorelin', without time restriction. Duplicates were deleted. Relevant conference abstracts were also screened. A total of 16 direct comparative trials were identified: 12 reported on efficacy outcomes, four on safety/tolerability, and five on the convenience of administration/user perceptions. These studies are restricted in terms of patient numbers, formulations assessed, and endpoints measured; none were adequately powered for survival outcome measures. Studies reporting on efficacy endpoints did not show major differences in the ability of these GnRH agonists to reduce levels of testosterone or prostate-specific antigen. Some studies suggest differences in short-or long-term testosterone control, the rate of injection site adverse events, and patient/healthcare professional perceptions, but definitive conclusions cannot be drawn from the existing evidence. Few direct comparative trials of GnRH agonists have been conducted. Whilst GnRH agonists provide a similar castration effect, there is not enough evidence to show that GnRH agonists are equivalent.
Introduction
As testosterone stimulates the growth of cancerous prostate cells, reducing the circulating level of testosterone to that achieved by surgical castration is the goal of androgendeprivation therapy (ADT) for prostate cancer [1, 2] . ADT is indicated for high-risk localised, locally advanced or metastatic prostate cancer [3] . Castration can be achieved with bilateral orchidectomy or treatment with a GnRH agonist or antagonist [1, 3] . GnRH agonists are the most widely used form of ADT, and are often used in combination with radiotherapy or radical prostatectomy [3] .
Gonadotrophin-releasing hormone is a decapeptide produced by the hypothalamus that induces the release of LH and FSH from the pituitary [4] . LH is responsible for the production of testosterone by the testes [5] . Long-term administration of a GnRH agonist brings about a sustained reduction of testosterone production through desensitisation of the pituitary GnRH receptors [6] .
The widely available GnRH agonists, leuprorelin, triptorelin and goserelin, are all decapeptides derived from GnRH, with different modifications to the amino acid residues at positions 6 and 10. The resultant affinity for binding to the GnRH receptor is 50-fold higher for goserelin and leuprorelin, and 100-fold higher for triptorelin than it is for endogenous GnRH [7] . In vitro, in COS-1 cells expressing the human GnRH receptor, triptorelin was six times more active than leuprorelin in receptor binding [8] . GnRH agonists typically have short half-lives (4.9 h for goserelin and 2.8 h for triptorelin, for example [9, 10] ), which renders them incompatible with chronic parenteral administration [10, 11] . Sustained-release formulations of each of these products have been developed to reduce the number of injections, improve convenience, and increase adherence [1, 12] . Modern formulations of GnRH agonists consist of biocompatible biodegradable polymeric matrices, delivered by either subcutaneous (s.c.) or intramuscular (i.m.) injection. The rate of release of the active compound from the matrix can be controlled by varying the molecular weight of the polymer and the solvent concentration, permitting the development of long-acting depot formulations that provide sustained release of GnRH agonist therapy over 1, 3 or 6 months [13] [14] [15] . Where studies have been conducted, the pharmacokinetic and pharmacodynamic equivalence of the different formulations of the same GnRH agonist has been confirmed [16] [17] [18] . Likewise, the route of administration (i.m. or s.c.) appears to have minimal impact upon the pharmacological suppression of testosterone [19] . The pharmacokinetic properties of these formulations are summarised in Table 1 [12, [20] [21] [22] [23] [24] [25] [26] [27] .
Given that a 'class-effect' is often assumed for drugs belonging to the same therapeutic class, it is possible that many clinicians use the different GnRH agonists interchangeably. However, equivalence of any two GnRH agonists has not been definitively confirmed in a direct comparison in a randomised clinical trial [28] . Indeed, there are few clinical trials on which to make evidenced-based decisions on their comparative efficacy, safety, tolerability, effect on quality of life (QoL), ability to reduce LUTS, and convenience of administration. If equivalence of different GnRH agonists is assumed, this is done without robust supporting data. The present systematic review was therefore conducted to examine the existing comparative data of the three most widely used GnRH agonists, and to highlight gaps in our knowledge.
Methods
The study protocol was registered on the PROSPERO international prospective database of systematic reviews (CRD42017068725) and analysis was performed in accordance with recommendations outlined in the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) Statement [29] .
Search Strategy
In June 2017, the following searches were performed in PubMed: (i) 'prostate cancer' and 'triptorelin' and 'leuprorelin', (ii) 'prostate cancer' and 'leuprorelin' and 'goserelin' (iii), and 'prostate cancer' and 'goserelin' and 'triptorelin', without time restriction. Duplicate references were deleted. Abstracts from the 2015 and 2016 (and 2017 where available) annual meetings of the European Society of Medical Oncology (ESMO), American Society of Clinical Oncology (ASCO), European Association of Urology (EAU), AUA, and BAUS were screened for comparative studies of these GnRH agonists. Publications of clinical trials and pharmacokinetic studies were included, but review articles, unless they added novel information, were excluded. Key publications from single-product searches were used to inform the discussion. The searches and screening were conducted independently by two researchers within the same month.
Inclusion Criteria
Publications of clinical trials of direct comparisons between two or more GnRH agonists were included. Studies reporting on testosterone and PSA levels, survival outcomes, LUTS, safety, tolerability, QoL, symptoms, and convenience of administration were eligible for inclusion.
Level of Evidence
An adapted version of the 'Oxford Centre for Evidence-Based Medicine' system was used to define the level of evidence (Table 2 ) [30] . [26] i.m./s.c. C max = 35.70 ng/mL T max = 2.50 h Circulating levels = 0.06 AE 0.05 ng/mL 6-month [23] i.m. T max = 3.00 (2) (3) (4) (5) (6) (7) (8) (9) (10) (11) (12) 
Results
The initial searches identified 246 references of potential interest ( Fig. 1 ). From these, 16 direct comparison studies met the inclusion criteria; 12 reported efficacy outcomes (Table 3 ) [31] [32] [33] [34] [35] [36] [37] [38] [39] [40] [41] [42] , four reported safety and tolerability data (Table 4) [35, 36, 40, 43] , and five reported on the convenience of administration/user perceptions of GnRH agonists (Table 5 ) [35, [43] [44] [45] [46] .
Efficacy

Achievement of Castrate Levels of Testosterone
We identified several randomised trials comparing testosterone control achieved with goserelin and leuprorelin. A small study comparing 1-month leuprorelin 3.75 mg, 1-month leuprorelin 7.5 mg, and 1-month goserelin showed more patients with advanced prostate cancer achieved testosterone levels of ≤20 ng/dL with the higher dose (7.5 mg) of leuprorelin than in the other groups (Level 2; Fig. 2 ) [31] . Median testosterone levels were also lower in the higher dose (7.5 mg) leuprorelin group than in the lower dose (3.75 mg) leuprorelin group (Level 2) [32] . However, this difference must be considered with caution as a simultaneous comparison of the three groups did not reach the established significance level. A study in Japanese men (mixed population of metastatic and non-metastatic prostate cancer) also showed equivalent testosterone castration levels with 1-and 3-month formulations of goserelin and leuprorelin (Level 4) [33] .
Leuprorelin and triptorelin have been compared in three randomised trials. A small randomised clinical trial reported a higher proportion of patients with prostate cancer not suitable for surgery with testosterone levels of <1.0 nmol/L (<29 ng/dL) 2 months after treatment initiation in the triptorelin 1-month group than in the leuprorelin 1-month group (P = 0.02) (Level 2) [34] . However, other studies have given conflicting results. For example, one study of men with metastatic prostate cancer suggested significantly higher mean plasma testosterone levels 1 month after first injection with 1-month triptorelin than with 1-month leuprorelin (but not at 3 or 6 months), but a similar proportion of patients achieved castrate levels of testosterone (≤50 ng/dL) at 1, 3, and 6 months (Level 2) [35] . Comparing the 1-month formulations of triptorelin and leuprorelin, Heyns et al. [36] reported a higher proportion of patients with advanced prostate cancer achieving castrate testosterone levels (testosterone ≤50 ng/dL) at 29 days in the leuprorelin arm than in the triptorelin arm, but similar proportions at later time points (Level 2; Fig. 3 ) [36] . These three studies, all with short follow-ups and only comparing the 1-month formulations, provide limited information on the relative efficacies of leuprorelin and triptorelin.
We identified only one comparison of goserelin and triptorelin, which was in the pre-radiotherapy setting in patients with localised prostate cancer [37] . Testosterone levels of ≤0.5 nmol/L (≤14 ng/dL) were achieved by a similar proportion of patients and at a similar time in both groups (Level 2; Fig. 4 ) [37] .
Maintenance of Castrate Levels of Testosterone
Equally important as achieving castration is the ability to maintain castrate levels of testosterone over time. The risk of testosterone breakthrough was higher with s.c. leuprorelin (10.9%) than with either goserelin (4.8%) or i.m. leuprorelin (5.1%) (Level 4) [38] . The use of anti-androgens to achieve complete androgen blockade was not reported in this study, but between 13% and 31% of patients with breakthroughs were managed by unspecified actions (usually by the addition of anti-androgens). Another study suggested higher testosterone levels during the testosterone 'flare' with leuprorelin than with goserelin (in the absence of antiandrogen) [39] . In the Heyns et al. [36] study, in a 24-h period at the 3-month assessment, breakthrough increases of serum testosterone of >50 ng/dL were experienced by three patients in the leuprorelin group compared with no patients in the triptorelin group (anti-androgen use was not permitted in this study).
Reduction in PSA
In the study of Reis et al. [32] , 3 months after the first injection, patients with metastatic prostate cancer treated with 1-month goserelin had significantly lower PSA levels than patients treated with 1-month leuprorelin 3.75 mg or 1-month leuprorelin 7.5 mg. However, the reduction in PSA level did not correlate with the reduction in testosterone in this study [32] . In all, 20 patients were included in each group in this study, and therefore, larger scale studies would be needed to determine if goserelin suppressed PSA more effectively than leuprorelin (Level 3). Table 2 Levels of evidence [30] .
Level of evidence Description
1
Evidence from at least one large randomised, controlled trial of good methodological quality (low potential for bias) or metaanalyses of well-conducted randomised trials without heterogeneity 2
Small randomised trials or large randomised trials with a suspicion of bias (low methodological quality) or meta-analyses of such trials or of trials with demonstrated heterogeneity 3
Prospective cohort studies 4
Retrospective cohort studies of case-control studies 5
Studies without control group, case reports, expert opinions
Studies comparing leuprorelin with triptorelin did not find obvious differences in the ability of these compounds to reduce circulating levels of PSA. For example, in the study of Abbou et al. [35] in metastatic prostate cancer, mean PSA (standard deviation [SD]) levels across the treatment groups were 1 694 (5 344) ng/mL at the start of the trial and 118 (547) ng/mL at 6 months, without significant differences between the treatment groups (Level 2).
No direct comparative data comparing the effects of goserelin and triptorelin on PSA levels were identified.
Survival
When used as part of a complete androgen blockade regimen, the 1-month formulations of goserelin and leuprorelin were not significantly different for either survival or progression [40] . Notably, this was an exploratory analysis carried out 20 years ago, and the therapeutic landscape for prostate cancer has changed considerably since this trial. In the Heyns et al. [36] study, the 9-month survival rate was higher in the triptorelin arm than in the leuprorelin arm (97.0% vs 90.5%, respectively; P = 0.033). Although this study recruited 284 men, it was not powered to detect a difference in survival rate between treatments and this result should be interpreted with caution. No other survival data from direct comparative studies were identified.
Safety and Tolerability
Comparative studies reporting on safety and tolerability are summarised in Table 4 . The most frequently reported adverse events (AEs) with GnRH agonists are hot flushes, skeletal pain, headache, and constipation [35, 36] ; vision impairments, headaches, and dizziness have also been reported at a lower frequency [35] . Leuprorelin and triptorelin appear to have a similar toxicity profile: nausea and dizziness were reported at a higher incidence with triptorelin than with leuprorelin (Level 2) [35, 36] , but the incidence of respiratory system disorders was higher with leuprorelin than with triptorelin [36] . One study reported an increase in heart rate with triptorelin compared with leuprorelin, whilst another did not report any change [35, 36] . Other cardiovascular events have not been reported. Injection site reactions (e.g., swelling, bruising, and pain) had a similarly low incidence in the triptorelin and leuprorelin arms [36] . In one study, patients reported higher discomfort from injection, including injection site 'burning or stinging', with leuprorelin than with triptorelin [43] . ADT use is linked to an increased risk of non-metastatic bone fractures. 
Convenience of Injection
The perceptions of users (patients and/or nurses) of GnRH agonists were evaluated in five studies (Table 5 ). In a comparative study of the administration processes, nurses preferred the goserelin to the leuprorelin injection system [44] . The injection of leuprorelin is performed with a 23-G needle under the supervision of a physician [47, 48] . Goserelin is administered s.c. as an implant with a pre-filled syringe with a 16-G needle under the supervision of a physician [20, 49] . However, patients unaware of the needle size did not report any difference in injection pain between goserelin and leuprorelin [45] . Patients recruited in a randomised crossover trial rated leuprorelin better than goserelin on a visual analogue scale of discomfort [46] . Triptorelin was associated with a more favourable tolerability profile, including less soreness, discomfort, redness and itching. The convenience of triptorelin vs leuprorelin was compared in two studies. In one study, 93% of patients in both groups (triptorelin or leuprorelin) rated the tolerability as satisfactory [35] . In a crossover, open-label study, patients' and physicians' perceptions of tolerability were compared for i.m. triptorelin and s.c. leuprorelin, using a visual analogue rating scale [43] . Patients and clinicians reported greater satisfaction with triptorelin than with leuprorelin [43] . Patient satisfaction was based on tolerability at the injection site and injectionrelated anxiety, and clinician satisfaction was based on efficiency of injection and convenience [43] .
Data comparing the injection convenience of triptorelin with goserelin are lacking.
Discussion
Efficacy
There have been few direct comparisons of the efficacy of leuprorelin, triptorelin and goserelin, which makes it difficult to judge their pharmacological equivalence. Comparative studies have comprised small cohorts, most of which have not been blinded. Some small differences in testosterone suppression and consistent maintenance of testosterone suppression have been noted between products in these direct comparative studies, mainly in advanced prostate cancer (i.e., a mix of locally advanced metastatic prostate cancer). Noncomparative trials show that 1-, 3-and 6-month formulations of leuprorelin effectively suppress testosterone levels in >90% of patients (reviewed by Wex et al. [50] ), with castration maintained for at least 12 months [21, 51, 52] . Few studies have assessed the relative impact of leuprorelin on testosterone levels in patients with different stages of prostate cancer. Most non-comparative studies have included mixed populations of patients with localised, locally advanced or metastatic prostate cancer. When specific populations have been recruited into trials, the control of testosterone levels appears similar between, for example, patients with localised prostate cancer [53] and patients with locally advanced prostate cancer [22] .
Likewise, triptorelin 1-, 3-and 6-month formulations suppress testosterone to castration levels (≤50 ng/dL) in >90% of patients from day 29 after the first injection (reviewed in Ploussard and Mongiat-Artus [54] , and Breul et al. [55] ), and this testosterone suppression is maintained over the long-term (33 months) [56] . Different formulations of goserelin are effective at controlling testosterone levels, an effect that has been shown to persist in the long term [18, 57] . Leuprorelin and triptorelin have also been shown to achieve the lower testosterone threshold value of ≤20 ng/dL in >90% of patients in non-comparative studies [54, 55, 58, 59] , but data on the ability of goserelin to achieve lower testosterone levels are lacking. A recent evidence-based review highlighted that [37] .
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© 2018 The Authors BJU International © 2018 BJU International suppression of testosterone to lower than the historic standard threshold level of <50 ng/dL may have implications for improved disease control and lead to improved clinical outcomes [60] . For example, in a recent post hoc analysis of the ICELAND study (a phase IIIb randomised study of intermittent vs continuous androgen-deprivation therapy using Eligard â 22.5 mg 3-month depot in subjects with relapsing and locally advanced prostate cancer who are responsive to such therapy), a lower testosterone nadir level was associated with a trend toward longer time to PSA progression (≤20 ng/dL vs >20-50 ng/dL; hazard ratio 5.06; 95% CI, 1.3-16.1; P = 0.062) [61] . As with leuprorelin, it is not possible from published literature to determine any obvious differences in the impact of triptorelin or goserelin on testosterone levels in different prostate cancer stages.
In the Heyns et al. [36] study, although fewer patients treated with triptorelin achieved castrate levels of testosterone by 29 days compared with patients receiving leuprorelin, fewer patients in the triptorelin group experienced at least one breakthrough between 2 and 9 months. One theory for this is that although the higher dose (7.5 mg) of leuprorelin may bring about castration more rapidly than the lower dose (3.75 mg) of triptorelin, repeated exposure to the high doses may increase testosterone breakthrough due to weak desensitisation of pituitary GnRH receptors. Testosterone breakthroughs, despite continuous administration of GnRH agonist therapy, may have clinical consequences. A retrospective study showed a relationship between testosterone breakthroughs and survival free of androgenindependent progression. Mean progression-free survival in patients with breakthrough increases >32 ng/dL was 88 months (95% CI 55-121), compared with 137 months (95% CI 104-170) for patients without such breakthroughs (P < 0.03) [62] .
The absence of direct comparative data prevents firm conclusions being made on the possible differential effects of the three GnRH agonists on PSA levels. A wealth of data from non-comparative trials have shown the ability of different long-acting formulations of leuprorelin, triptorelin, and goserelin to reduce and maintain PSA levels at ≤4 ng/mL for 1-7 years [23, 52, 54, 56, 63] .
Survival data from comparative studies are limited. The 5-year survival rates in non-comparative trials with GnRH agonists are 75-85% [63] [64] [65] . Differences in patient characteristics and other therapies between trials make comparisons of survival rates unreliable. A recent report suggested a survival improvement with triptorelin compared with degarelix, whilst leuprorelin and goserelin appeared to be associated with worse survival outcomes than degarelix [66] . On that basis, it was reasoned that triptorelin may have a different effect on survival compared with leuprorelin and goserelin [66] .
When we initiated this systematic review, we were aware of several recent publications on the impact of GnRH agonists on LUTS. As the severity of these symptoms of prostate cancer are associated with a reduced patient QoL, as shown in an analysis of data from almost 6 500 men aged 40-79 years [67] , a comparison of the effects of different GnRH agonists on LUTS would be invaluable for patients and physicians. However, no direct comparative studies identified in the present review reported LUTS as an endpoint. A prospective single-arm study of 1-month goserelin combined with bicalutamide reported a nonsignificant reduction in the IPSS from 11.7 (SD 1.6) at baseline to 9.3 (SD 1.0) at week 12 (P = 0.15) and 9.3 (SD 1.0) at week 24 (P = 0.2) [68] . This study was consistent with previous reports of the beneficial effects of goserelin on LUTS [69, 70] . However, in another study, reductions in IPSS were greater in patients treated with the GnRH antagonist degarelix than in those receiving the combination of goserelin and bicalutamide [71] . Recent noninterventional studies have suggested an improvement in LUTS induced by triptorelin, as measured by the IPSS [72] [73] [74] . In one study, mean total IPSS was reduced from 18.2 (95% CI 17.8-18.5) at baseline to 11.9 (95% CI 11.5-12.3; P < 0.001) and 10.6 (95% CI 10.2-11.0; P < 0.001) at weeks 24 and 48, respectively [72] . In a prospective analysis of data from patients with locally advanced or metastatic prostate cancer receiving triptorelin, as well as significant LUTS improvements, there were significant reductions in the adjusted mean QoL score related to urinary symptoms at weeks 24 and 48 (P < 0.001 for both vs baseline) [74] . We found no data on the effect of leuprorelin on LUTS.
Safety and Tolerability
As with the efficacy data, the few comparative trials on safety and tolerability were short-term and had low patient numbers, making it difficult to detect AEs with a low frequency. In single-agent clinical trials of leuprorelin, triptorelin or goserelin, the AE profiles have been broadly similar [52, 56, 75] . Goserelin and leuprorelin were compared in combination with two anti-androgens (bicalutamide and flutamide) as part of exploratory analyses of data from a controlled trial [40] . Toxicity profiles were similar between the groups receiving goserelin and those receiving leuprorelin. Increases in the QT interval have been reported with leuprorelin and goserelin alone or combined with bicalutamide [76] . Although we identified no reports of torsades de pointes with GnRH agonists and GnRH agonists do not seem to increase cardiovascular mortality in men with locally advanced prostate cancer [77] , the findings on QT interval warrant an assessment of the risks and benefits of hormonal therapy in patients with baseline QT value >450 ms and who are taking Class IA or III anti-arrhythmics [76] . Case reports have described the occurrence of granulomas at the injection site with GnRH agonist injections [78] [79] [80] [81] [82] , which may be due to the GnRH analogue itself or to another constituent of the formulation [83] . Pituitary apoplexy [84] [85] [86] , interstitial pneumonitis [87] , and anaphylaxis [88] have also all been reported after GnRH agonist administration. These AEs seem to have a low incidence and it remains to be established whether they are connected to a specific agent or represent a class effect of GnRH agonist therapy. Despite the apparent similarities between AE profiles of GnRH agonists, patient reports of discomfort suggest patient perception of these AEs may differ between agents.
Long-term AEs have not been assessed in comparative studies. The long-term use of ADT is potentially associated with flushing, erectile dysfunction, fatigue, gynaecomastia, anaemia, osteoporosis, obesity, and metabolic or cardiovascular complications [89] . A long-term follow-up study of men receiving leuprorelin 3-month formulation for up to 43 months reported hot flushes, decreased libido, erectile dysfunction, increase sweating, nocturia, and weight increase as AEs occurring with a frequency of ≥15% -but those occurring after the initial 9-month treatment period were not reported separately [51] . In 180 patients receiving triptorelin for up to 3 years, ADT-related AEs reported after the first 9 months of treatment included gynaecomastia (three patients; 1.7%), increased weight (three; 1.7%), hot flushes (two; 1.1%), asthenia (one; 0.6%), and erectile dysfunction (one; 0.6%) [56] . During 9 months of treatment with triptorelin or leuprorelin, the increased weight was not significantly different between treatment groups [36] . Goserelin and leuprorelin, when used as part of a complete androgen-blockade regimen, resulted in similar AEs as described above over a median follow-up of 160 weeks, but the timing of these events during treatment (early, late or throughout treatment) was not specified [40] . The potential impact of long-term ADT on metabolic or cardiovascular health remains uncertain, and the data do not allow any conclusions on the different effects of different GnRH agonists.
Patients reported greater satisfaction with triptorelin than with leuprorelin, and higher discomfort from injection with leuprorelin than with triptorelin. A comparative analysis based on a PubMed search of clinical trials of the 6-month formulations of triptorelin and leuprorelin supports this result, showing greater local tolerability with triptorelin than with either the i.m. or s.c. leuprorelin injections [90] .
Convenience
The three widely used GnRH agonists are available in multiple formulations and are delivered to the patient using slightly different equipment (needle size, etc.). Even if we are to assume a similar efficacy and safety of these products, practical differences in the syringe design and injection experience may influence the perception of, and preference for, one agent over another, and could impact on the QoL of the patient. All GnRH analogues are administered under the supervision of a healthcare professional. Leuprorelin comes as a powder and solvent for s.c. injection in a pre-filled syringe, using a 23-G needle [47, 48] . Some formulations of leuprorelin come in two pre-filled sterile syringes, the contents of which require mixing prior to s.c. administration using a 20-G needle [91] . Triptorelin is administered either s.c. into the skin of the abdomen, the buttock, or thigh or i.m. [24, 92, 93] . It comes as a powder that is reconstituted with a solvent, with the injection performed with a 20-G needle [24, 92, 93] . Goserelin is administered s.c. as an implant in a pre-filled syringe with a 16-G needle [20, 49] . Some studies have investigated patient and healthcare professional perceptions of the GnRH agonists, and these suggest considerable differences in both healthcare provider and patient perception of the different products. Assessing patient preferences and the potential causes of these could be an important future goal, to gain more insight on this issue and help optimise the treatment experience for patients.
Limitations
There were several limitations to the comparative data we identified in this systematic analysis. Comparisons are largely confined to 1-month formulations but 3-and 6-month formulations are more widely used in many countries. The sample sizes of the direct comparisons were often small, and there were notably few direct comparisons of goserelin and triptorelin.
There are therefore clear gaps in our knowledge regarding the similarities and differences between leuprorelin, triptorelin, and goserelin. It is important to consider this in the context of taking an evidence-based approach to treating patients. Evidence-based medicine is the integration of personal experience, best external evidence and the patient's values [94] . When comparing treatments, a large randomised clinical trial or systematic reviews of randomised trials provide Level 1 evidence (Table 2 ) [94] . From the present systematic literature review, most studies were randomised trials with small patient numbers, thereby giving Level 2 evidence at best. To this end, there is insufficient evidence to help guide an evidence-based approach when choosing between these different GnRH agonists, and importantly, there is insufficient evidence to conclude that these GnRH agonists are equivalent.
Conclusions
The few published direct comparisons of GnRH agonists in prostate cancer that exist do not allow firm conclusions to be drawn on the similarities or differences between leuprorelin, triptorelin, and goserelin, in terms of efficacy, safety, and convenience of use. The ability of these compounds to induce 380 © 2018 The Authors BJU International © 2018 BJU International and maintain castration levels of testosterone and reduce PSA has been proven in large scale studies of single agents. Nevertheless, in the absence of robust comparative survival and toxicity data, the assumption of equivalent efficacy and safety of these agents may be erroneous. Some differences in the maintenance of testosterone suppression, survival, patient perception of tolerability, and patient satisfaction have been reported with these products and this may cast doubt on assumptions of equivalence. Maintenance of QoL and reduction in symptoms are important patient-centric outcomes, but direct comparative studies have not included these as endpoints, and improvement in LUTS have been shown with some but not all GnRH agonists. A similar analysis to the present review was published in 2010 and concluded that there was not enough evidence to support an assumed class effect amongst GnRH agonists [95] . Since then, insufficient novel data have emerged to warrant a change in this conclusion.
